Drugs / AROG4-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06652529 | Jan → Dec 2025 overdue | colorectal carcinoma, mesothelioma, non-small cell lung carcinoma, ovarian cancer | Aromics Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AROG4-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06652529 ↗ |
| Route | Intravenous | “AROG4-01 will be administered as IV infusions in biweekly dosing interval.” NCT06652529 ↗ |